Alerts will be sent to your verified email
Verify Email
PGHL
|
Procter&Gamble Healt
|
Marksans Pharma
|
Viyash Scientific
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
20.1 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
36.03 % | 17.57 % | 4.43 % |
|
5yr average Equity Multiplier
|
1.79 | 1.33 | 2.16 |
|
5yr Average Asset Turnover Ratio
|
0.77 | 0.9 | 0.95 |
|
5yr Avg Net Profit Margin
|
19.19 % | 14.56 % | 0.03 % |
|
Price to Book
|
13.67 | 3.35 | 11.6 |
|
P/E
|
28.86 | 24.98 | 122.23 |
|
5yr Avg Cash Conversion Cycle
|
-155.74 Days | 71.65 Days | 49.09 Days |
|
Inventory Days
|
36.01 Days | 89.77 Days | 80.25 Days |
|
Days Receivable
|
40.92 Days | 65.99 Days | 79.76 Days |
|
Days Payable
|
215.28 Days | 88.81 Days | 114.46 Days |
|
5yr Average Interest Coverage Ratio
|
500.05 | 38.03 | 1.93 |
|
5yr Avg ROCE
|
30.21 % | 21.95 % | 6.67 % |
|
5yr Avg Operating Profit Margin
|
27.53 % | 20.32 % | 7.74 % |
|
5 yr average Debt to Equity
|
0.0 | 0.02 | 0.53 |
|
5yr CAGR Net Profit
|
4.02 % | 10.03 % | -25.52 % |
|
5yr Average Return on Assets
|
15.5 % | 13.19 % | 0.05 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
51.82 % | 43.87 % | 61.31 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.02 % | 8.52 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
2.86 % | 3.8 % | 6.19 % |
|
Procter&Gamble Healt
|
Marksans Pharma
|
Viyash Scientific
|
|
|---|---|---|---|
|
Segment Break-Up
|
Segment Break-Up
|
-
|
Segment Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Drug Delivery Break-Up
|
Drug Delivery Break-Up
|
-
|
-
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
Therapeutic Area Break-Up
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
Asset Break-Up
|